The mTORC1/mTORC2 Inhibitor AZD2014 Enhances the Radiosensitivity of Glioblastoma Stem-like Cells

被引：0
|
作者：
Kahn, J. [1 ]
Hayman, T. J. [1 ]
Camphausen, K. [1 ]
Tofilon, P. J. [1 ]
机构：
[1] NCI, Bethesda, MD 20892 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2012年 / 84卷 / 03期
关键词：
D O I：
10.1016/j.ijrobp.2012.07.1863
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S697 / S697
页数：1
相关论文
共 50 条
  • [1] The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells
    Kahn, Jenna
    Hayman, Thomas J.
    Jamal, Muhammad
    Rath, Barbara H.
    Kramp, Tamalee
    Camphausen, Kevin
    Tofilon, Philip J.
    NEURO-ONCOLOGY, 2014, 16 (01) : 29 - 37
  • [2] Dramatic antitumor effects of the dual mTORC1 and mTORC2 inhibitor AZD2014 in hepatocellular carcinoma
    Liao, Hui
    Huang, Yu
    Guo, Botang
    Liang, Bo
    Liu, Xincheng
    Ou, Huohui
    Jiang, Chenglong
    Li, Xianghong
    Yang, Dinghua
    AMERICAN JOURNAL OF CANCER RESEARCH, 2015, 5 (01): : 125 - 139
  • [3] The combination of the dual mTORC1/mTORC2 inhibitor AZD2014 and paclitaxel in human ovarian cancer models
    Stewart, Adam
    Thavasu, Parames
    Heaton, Simon
    Banerjee, Susana
    Kaye, Stan B.
    Banerji, Udai
    CANCER RESEARCH, 2012, 72
  • [4] AZD2014, a dual mTORC1 and mTORC2 inhibitor is differentiated from allosteric inhibitors of mTORC1 in ER+ breast cancer
    Guichard, Sylvie M.
    Howard, Zoe
    Heathcote, Dan
    Roth, Mark
    Hughes, Gareth
    Curwen, Jon
    Yates, James
    Logie, Armelle
    Holt, Sarah
    Chresta, Christine M.
    Davies, Barry R.
    Malagu, Karine
    Hummersone, Marc
    Pass, Sarah L.
    Green, Stephen
    Pass, Martin
    CANCER RESEARCH, 2012, 72
  • [5] Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014
    Pike, Kurt G.
    Malagu, Karine
    Hummersone, Marc G.
    Menear, Keith A.
    Duggan, Heather M. E.
    Gomez, Sylvie
    Martin, Niall M. B.
    Ruston, Linette
    Pass, Sarah L.
    Pass, Martin
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (05) : 1212 - 1216
  • [6] First-in-human phase I trial of the dual mTORC1 and mTORC2 inhibitor AZD2014 in solid tumors
    Banerji, Udai
    Dean, Emma Jane
    Gonzalez, Michael
    Greystoke, Alastair P.
    Basu, Bristi
    Krebs, Matthew
    Puglisi, Martina
    Grinsted, Lynda
    Oelmann, Elisabeth
    Burke, Wendy
    Harrington, Elizabeth
    Green, Stephen
    Ranson, Malcolm
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] The mTORC1 inhibitor rapamycin and the mTORC1/2 inhibitor AZD2014 impair the consolidation and persistence of contextual fear memory
    Phillip E. MacCallum
    Jacqueline Blundell
    Psychopharmacology, 2020, 237 : 2795 - 2808
  • [8] The mTORC1 inhibitor rapamycin and the mTORC1/2 inhibitor AZD2014 impair the consolidation and persistence of contextual fear memory
    MacCallum, Phillip E.
    Blundell, Jacqueline
    PSYCHOPHARMACOLOGY, 2020, 237 (09) : 2795 - 2808
  • [9] Anticancer activity of the mTOR inhibitor (everolimus) and dual mTORC1/mTORC2 Inhibitor (AZD2014) on mouse lymphocytic leukemia both in vitro and in vivo
    Su, Y-C.
    Liao, H-F.
    Yu, C-C.
    Lin, Y-C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [10] Differential functions of mTORC1 and mTORC2 in the maintenance of stem-like properties of pancreatic cancer cells
    Matsubara, Shyuichiro
    Tsukasa, Koichiro
    Kuwahata, Taisaku
    Obara, Toru
    Matsuyama, Takami
    Takao, Sonshin
    CANCER SCIENCE, 2018, 109 : 703 - 703
12345